VICKS COLD & FLU MAX STRENGTH

Method of administration Dissolve the contents of one sachet in a standard mug of hot, but not boiling, water (approx. 250ml). Allow to cool to a drinkable temperature.

Posology Adults:

One sachet. May be repeated every 4-6 hours as required Adolescents aged 16 years of age and over: One sachet. May be repeated every 6 hours as required. Maximum of 4 doses (4 sachets) in 24 hours.

Paediatric population:

Vicks Cold & Flu Max Strength is contraindicated in children under 16 years of age.

Elderly:

No special dosage modifications are required.

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. The corresponding frequency category for each undesirable effect is based on the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000).

Skin and subcutaneous tissue disorders: hypersensitivity including skin rash and urticaria (rare), serious skin reactions (very rare). g. thrombocytopenia, agranulocytosis, haemolytic anaemia, neutropenia, leucopenia, pancytopenia (very rare).

Immune system disorders: allergic or hypersensitivity reactions, including anaphylaxis and bronchospasm, urticaria and skin rashes (rare). Nervous system disorders: insomnia, nervousness, tremor, anxiety, restlessness, confusion, irritability and headache (rare).

Cardiac disorders: tachycardia (rare). Vascular disorders: high blood pressure with palpitations, headache and vomiting (rare). Gastrointestinal disorders: anorexia, nausea and vomiting (common). Hepatobiliary disorders: liver function test abnormal (elevation of hepatic aminotransferase levels) (very rare).

Metabolism and nutrition disorders:

Frequency not known: High anion gap metabolic acidosis. 4). Pyroglutamic acidosis may occur as a consequence of low glutathione levels in these patients. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard.

Paracetamol should be administered only with particular caution in patients with impaired hepatic function, including acute hepatitis, alcoholism, haemolytic anaemia or patients taking hepatotoxic medicinal products. Use of paracetamol in patients with impaired hepatic function and in patients receiving long-term therapy with high doses of paracetamol requires the regular monitoring of hepatic function.

Paracetamol should be administered with particular caution in patients with chronic malnutrition (low reserves of hepatic glutathione) or Glucose-6- phosphate dehydrogenase deficiency. Use with caution in patients with hyperthyroidism.

Use with caution in patients receiving digitalis, beta-adrenergic blockers, methyldopa or other anti- hypertensive agents. Use with caution in patients with prostatic hypertrophy as they may be susceptible to urinary retention. Use with caution in patients with Raynaud’s Phenomenon or diabetes.

Sympathomimetic-containing products may act as cerebral stimulants giving rise to insomnia, nervousness, hyperpyrexia, tremor, and epileptiform convulsions. Concurrent use with halogenated anesthetic agents such as chloroform, cyclopropane, halothane, enflurane or isoflurane may provoke or worsen ventricular arrhythmias.

, chronic alcoholism) who were treated with paracetamol at therapeutic dose for a prolonged period or a combination of paracetamol and flucloxacillin. If HAGMA due to pyroglutamic acidosis is suspected, prompt discontinuation of paracetamol and close monitoring is recommended.

The measurement of urinary 5-oxoproline may be useful to identify pyroglutamic acidosis as underlying cause of HAGMA in patients with multiple risk factors. Contains aspartame (E951) a source of phenylalanine equivalent to 14 mg/dosage unit.

May be harmful for people with phenylketonuria. Contains sucrose. 75g. Patients with rare hereditary problems of fructose intolerance, glucose- galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

Contains Sodium. 875% of the WHO recommended maximum daily intake of 2 g sodium for an adult. Do not exceed the stated dose. Patients should be advised not to take with other paracetamol containing products. e. orally and topically (nasal, aural and eye preparations).

1; Severe ischaemic heart disease; Severe hepatic impairment; Moderate to severe renal impairment; Hypertension; Severe hyperthyroidism; Narrow-angle glaucoma; Use in patients who are currently taking or have taken monoamine oxidase inhibitors (MAOIs) within the last two weeks; Use in patients with urinary retention; Use in patients who are currently taking other sympathomimetic drugs; Use in children under 16 years of age.